Mostrar el registro sencillo del ítem

dc.rights.licenseopenen_US
hal.structure.identifierHôtel-Dieu de Nantes
hal.structure.identifierService de virologie [CHU Nantes]
dc.contributor.authorANDRE-GARNIER, Elisabeth
hal.structure.identifierService de Virologie [Lille]
dc.contributor.authorBOCKET, Laurence
hal.structure.identifierGroupe Immunité des Muqueuses et Agents Pathogènes [GIMAP]
dc.contributor.authorBOURLET, Thomas
hal.structure.identifierCentre Hospitalier Régional d'Orléans [CHRO]
dc.contributor.authorHOCQUELOUX, Laurent
hal.structure.identifierCentre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
hal.structure.identifierCarcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) [CEF2P / CARCINO]
dc.contributor.authorLEPILLER, Quentin
hal.structure.identifierEcophysiologie Végétale, Agronomie et Nutritions [EVA]
dc.contributor.authorMAILLARD, Anne
hal.structure.identifierMicrobiologie Fondamentale et Pathogénicité [MFP]
dc.contributor.authorREIGADAS, Sandrine
hal.structure.identifierGilead Sciences
dc.contributor.authorBARRIERE, Guillaume
hal.structure.identifierGilead Sciences
dc.contributor.authorDURAND, Francois
hal.structure.identifierCHU Montpellier
dc.contributor.authorMONTES, Brigitte
hal.structure.identifierCentre Hospitalier Régional Universitaire de Tours [CHRU Tours]
dc.contributor.authorSTEFIC, Karl
hal.structure.identifierCHU Pitié-Salpêtrière [AP-HP]
hal.structure.identifierStratégies thérapeutiques contre l'infection VIH et les maladies virales associées [iPLesp] [THERAVIR]
dc.contributor.authorMARCELIN, Anne-Geneviève
dc.date.accessioned2024-02-12T13:52:44Z
dc.date.available2024-02-12T13:52:44Z
dc.date.issued2024-01-23
dc.identifier.issn0305-7453en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/188050
dc.description.abstractEnAbstract Objectives:As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques, and interpretation of results.Methods: Based on a literature review and clinical experience, a Steering Committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October and December 2022. Results: The SC developed 20 statements grouped into six categories: clinical situations for the use of HIV DNA genotyping; techniques for performing HIV DNA genotyping; consideration of APOBEC mutations; genotyping results reporting; recycling of antiretrovirals; availability of HIV DNA genotyping tests and delays. Twenty-one virologists and 47 clinicians participated in two voting rounds and 18/20 (90%) assertions reached a ‘strong’ consensus. For example, that prior genotyping on HIV DNA is useful for clinical decision-making when considering switching to some long-acting regimens or to reduce the number of antiretroviral agents in virologically suppressed patients for whom RNA data are unavailable / not exploitable / not sufficiently informative. Two statements achieved no consensus: reporting any detected viral minority population for discussion in multidisciplinary meetings (virologists), and possible risk of virologic failure when using a second generation InSTI + XTC regimen in patients with undetectable viral load ≥1 year and in the presence of a documented M184V mutation <5 years (clinicians).Conclusion: This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.title.enUse of genotypic HIV DNA testing: a DELPHI-type consensus
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/jac/dkae007en_US
dc.subject.halSciences du Vivant [q-bio]en_US
dc.subject.halSciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologieen_US
dc.identifier.pubmed38269616en_US
bordeaux.journalJournal of Antimicrobial Chemotherapyen_US
bordeaux.hal.laboratoriesMFP (Laboratoire Microbiologie Fondamentale et Pathogénicité) - UMR 5234en_US
bordeaux.institutionCNRSen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcehal
hal.identifierhal-04423751
hal.version1
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
workflow.import.sourcehal
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20Antimicrobial%20Chemotherapy&amp;rft.date=2024-01-23&amp;rft.eissn=0305-7453&amp;rft.issn=0305-7453&amp;rft.au=ANDRE-GARNIER,%20Elisabeth&amp;BOCKET,%20Laurence&amp;BOURLET,%20Thomas&amp;HOCQUELOUX,%20Laurent&amp;LEPILLER,%20Quentin&amp;rft.genre=article


Archivos en el ítem

Thumbnail
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem